^
    over2years
    The CEA-targeted ISAC, BDC-2034, shows preclinical efficacy associated with innate immune activation, phagocytosis, and myeloid reprogramming (AACR 2022)
    These preclinical findings demonstrate the potential of BDC-2034 to generate anti-tumor activity in CEA-expressing cancers through direct innate immune activation and the induction of adaptive anti-tumor immunity.
    Preclinical • IO biomarker
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CEACAM5 (CEA Cell Adhesion Molecule 5) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CD40 (CD40 Molecule)
    |
    CEACAM5 expression
    |
    BDC-2034